FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3208294558> ?p ?o ?g. }

• W3208294558 endingPage "62" @default.
• W3208294558 startingPage "55" @default.
• W3208294558 abstract "Sativex (USAN: nabiximols [NAB]) oromucosal spray is indicated for treatment of multiple sclerosis (MS) patients with moderate to severe spasticity and inadequate response to other antispasticity medications who demonstrate clinically significant improvement during an initial trial of therapy. This narrative review investigated the efficacy and effectiveness of NAB oromucosal spray for moderate to severe MS spasticity by examining spasticity 0-10 numerical rating scale (NRS) data from interventional and observational studies which featured a 4-week trial period as per the European Union-approved label.Across both study types, clinically relevant and statistically significant reductions in mean MS spasticity 0-10 NRS scores were measured soon after treatment start and were maintained in the mid- to long term in treatment responders. Initial responder rates (≥20% NRS improvement from baseline at week 4) ranged from 47.6% to 81.4%, tending lower in the randomized clinical trials setting. Clinically relevant responder rates (≥30% NRS improvement from baseline at week 12) were similar between study types (range 30-41%) except for one outlier (74% in an observational study). Two open studies reported treatment continuation for ≥18 months in approximately half of patients who initiated treatment. In most longer term studies, symptomatic improvement in MS spasticity was maintained at mean daily dosages of about 6-7 sprays/day. Safety was consistent with the known profile of NAB.Experimental and observational studies of NAB oromucosal spray recorded similar findings. About half to two-thirds of MS patients who begin treatment will perceive initial symptomatic relief of spasticity within the 4-week trial period. About 40% of patients who initiate treatment will reach the ≥30% NRS improvement threshold at 3 months, comprising the majority of patients who continue long-term treatment. A trial of therapy with NAB is useful to identify patients most likely to gain longer term improvement in spasticity symptoms and discontinue those with insufficient benefit." @default.
• W3208294558 created "2021-11-08" @default.
• W3208294558 creator A5001808436 @default.
• W3208294558 creator A5058239803 @default.
• W3208294558 date "2021-01-01" @default.
• W3208294558 modified "2023-10-17" @default.
• W3208294558 title "Review of Available Data for the Efficacy and Effectiveness of Nabiximols Oromucosal Spray (Sativex®) in Multiple Sclerosis Patients with Moderate to Severe Spasticity" @default.
• W3208294558 cites W1790460690 @default.
• W3208294558 cites W1973987251 @default.
• W3208294558 cites W1981773361 @default.
• W3208294558 cites W1983777129 @default.
• W3208294558 cites W1995051534 @default.
• W3208294558 cites W2006295793 @default.
• W3208294558 cites W2069564502 @default.
• W3208294558 cites W2075560989 @default.
• W3208294558 cites W2081270129 @default.
• W3208294558 cites W2084776704 @default.
• W3208294558 cites W2100077258 @default.
• W3208294558 cites W2149459253 @default.
• W3208294558 cites W2160528939 @default.
• W3208294558 cites W2530652964 @default.
• W3208294558 cites W2876748213 @default.
• W3208294558 cites W2910591596 @default.
• W3208294558 cites W2922483223 @default.
• W3208294558 cites W3032918299 @default.
• W3208294558 doi "https://doi.org/10.1159/000520560" @default.
• W3208294558 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34731865" @default.
• W3208294558 hasPublicationYear "2021" @default.
• W3208294558 type Work @default.
• W3208294558 sameAs 3208294558 @default.
• W3208294558 citedByCount "10" @default.
• W3208294558 countsByYear W32082945582022 @default.
• W3208294558 countsByYear W32082945582023 @default.
• W3208294558 crossrefType "journal-article" @default.
• W3208294558 hasAuthorship W3208294558A5001808436 @default.
• W3208294558 hasAuthorship W3208294558A5058239803 @default.
• W3208294558 hasConcept C118552586 @default.
• W3208294558 hasConcept C126322002 @default.
• W3208294558 hasConcept C168563851 @default.
• W3208294558 hasConcept C1862650 @default.
• W3208294558 hasConcept C23131810 @default.
• W3208294558 hasConcept C2779012798 @default.
• W3208294558 hasConcept C2780640218 @default.
• W3208294558 hasConcept C535046627 @default.
• W3208294558 hasConcept C71924100 @default.
• W3208294558 hasConceptScore W3208294558C118552586 @default.
• W3208294558 hasConceptScore W3208294558C126322002 @default.
• W3208294558 hasConceptScore W3208294558C168563851 @default.
• W3208294558 hasConceptScore W3208294558C1862650 @default.
• W3208294558 hasConceptScore W3208294558C23131810 @default.
• W3208294558 hasConceptScore W3208294558C2779012798 @default.
• W3208294558 hasConceptScore W3208294558C2780640218 @default.
• W3208294558 hasConceptScore W3208294558C535046627 @default.
• W3208294558 hasConceptScore W3208294558C71924100 @default.
• W3208294558 hasIssue "3-4" @default.
• W3208294558 hasLocation W32082945581 @default.
• W3208294558 hasLocation W32082945582 @default.
• W3208294558 hasOpenAccess W3208294558 @default.
• W3208294558 hasPrimaryLocation W32082945581 @default.
• W3208294558 hasRelatedWork W1967947002 @default.
• W3208294558 hasRelatedWork W2091031254 @default.
• W3208294558 hasRelatedWork W2108965305 @default.
• W3208294558 hasRelatedWork W2318707379 @default.
• W3208294558 hasRelatedWork W2550575390 @default.
• W3208294558 hasRelatedWork W2616141209 @default.
• W3208294558 hasRelatedWork W2898310148 @default.
• W3208294558 hasRelatedWork W4210484722 @default.
• W3208294558 hasRelatedWork W4214506880 @default.
• W3208294558 hasRelatedWork W4312214387 @default.
• W3208294558 hasVolume "21" @default.
• W3208294558 isParatext "false" @default.
• W3208294558 isRetracted "false" @default.
• W3208294558 magId "3208294558" @default.
• W3208294558 workType "article" @default.